ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1276

Changes in B Cell Populations and Serum Immunoglobulins and Their Relationship to Infections in a One Year, Uncontrolled Open Label Study of Tabalumab

Maria W. Greenwald1, Melissa Veenhuizen2, Wendy Komocsar3, Rebecca Jones-Taha4, Chin H. Lee3 and Pierre-Yves Berclaz3, 1Desert Medical Advances, Palm Desert, CA, 2Eli Lilly and Company, Indianapolis, IN, 3Eli Lilly & Company, Indianapolis, IN, 4PharmaNet/i3, Blue Bell, PA

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: B cells and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Session Title: Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy

Session Type: Abstract Submissions (ACR)

Background/Purpose: B cell activating factor (BAFF) is an important modulator of B cell development and proliferation and is secreted by neutrophils, monocytes, macrophages and dendritic cells. Tabalumab, a monoclonal antibody that neutralizes both membrane-bound and soluble BAFF, has previously been shown to reduce the signs and symptoms of rheumatoid arthritis (RA)1,2. In this open label, uncontrolled , extension study, we examined the effect of tabalumab on B cell populations,  serum immunoglobulins (Ig) and the relationship between these parameters and infections.

Methods: One hundred eighty-six patients (pts) who completed one of two 24 week phase 2 trials of tabalumab versus placebo were elligible for this study, and 182 (98%) of those pts enrolled. Pts were methotrexate  or TNF antagonist inadequate responders. All pts received open label 60 mg subcutaneous tabalumab every 4 weeks for 48 weeks. The dose could be increased to 120 mg and, if necessary, decreased to 60 mg one time at the investigators’ discretion. B cell populations and serum Igs were compared to their pre-treatment baseline from the initial phase 2 studies. Total  B cell counts were monitored during a post study follow-up period.

Results: Sixty pts (33%) received 60 mg throughout the study, and 121 pts (66%) escalated to 120 mg at different times (60/120 mg group).One pt escalated to 120 mg then returned to 60 mg. In all groups, total B cell and mature naïve B cell  counts gradually declined over time but were not depleted at week 52 (table). Memory B cells increased  ~ 100% over baseline at week 12 and returned to ~ 60-70% over baseline at week 52. Sixty-six pts had total B cell counts < 43 cells/μl and < 50% of baseline at week 52 or after and the Kaplan-Meier estimate of median time to recovery after the last injection was 40.6 weeks (CI: 39.6-51.3).  All of these pts who completed follow up (n=47) recovered by 66 weeks. Among pts whose B cells decreased below  50% of baseline at any time during the treatment period, 37% had infections compared to 53% among pts whose  B cells did not. Serum Igs (IgA, IgM, IgG) decreased for all groups at week 52 (table).  Eleven pts had treatment-emergent  serum Ig levels below the lower limit of normal (LLN) during the treatment period with no concurrent infections.

Conclusion:

Tabalumab treatment reduced total B cells, mature naïve B cells and serum Igs, while memory B cells were increased. Total B cells were only partially depleted and recovered in all pts during the post treatment follow -up period.  There was no indication that reductions in B cells or in serum Igs below the LLN were associated with an increased frequency of infections. Additional studies will help further understand the effect of tabalumab treatment on B cells, serum Igs  and adverse events.

1. Genovese et al. Ann Rheum Dis 2011;70(Suppl3):611

2. Genovese et al. Ann Rheum Dis 2011;70(Suppl3):71

Change from Baseline in B Cell Populations and Serum Immunoglobulins at Week 52†

 

60 mg (N=60)

60/120 mg (N=121)

All pts* (N=182)

Total B cells         (CD20+)

(n=59)

-41.1 %

(n=118)

-34.7 %

(n=178)

-37.1 %

Mature naïve B cells (CD19+ IgD+ CD27-)

(n=59)

-65.8 %

(n=118)

-72.0 %

(n=178)

-70.1 %

Memory B cells    (CD19+ IgD- CD27+)

(n=59)

58.4 %

(n=118)

78.6 %

(n=178)

71.8 %

Serum IgA

(n=57)

-14.7 %

(n=121)

-13.5 %

(n=179)

 -13.8 %

Serum IgG

(n=57)

-10.9 %

(n=121)

-11.2 %

(n=179)

-11.1 %

Serum IgM

(n=57)

-18.7 %

(n=121)

-19.4 %

(n=179)

-19.1 %

†Last observation carried forward method was used to impute missing values at week 52. Small ‘n’ indicates the number of patients with both baseline and post baseline assessments

*1 pt that had dose escalated to 120 mg and decreased back to 60 mg is included in ‘all pts’ category


Disclosure:

M. W. Greenwald,

Eli Lilly and Company,

2;

M. Veenhuizen,

Eli Lilly and Company ,

3,

Eli Lilly and Company,

3;

W. Komocsar,

Eli Lilly and Company,

1,

Eli Lilly and Company,

3;

R. Jones-Taha,
None;

C. H. Lee,

Eli Lilly and Company,

1,

Eli Lilly and Company,

3;

P. Y. Berclaz,

Eli Lilly and Company,

1,

Eli Lilly and Company,

3.

  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/changes-in-b-cell-populations-and-serum-immunoglobulins-and-their-relationship-to-infections-in-a-one-year-uncontrolled-open-label-study-of-tabalumab/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.